Phathom Pharmaceuticals, Inc. PHAT Products & Services — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s products & services — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s products & services — revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) reported products & services — revenue of $58.3M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s products & services — revenue changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s products & services — revenue increased by 104.6% year-over-year, from $28.5M to $58.3M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s products & services — revenue?
- Over 2 years (2023 to 2025), Phathom Pharmaceuticals, Inc.'s products & services — revenue has grown at a 1481.6% compound annual growth rate (CAGR), from $700K to $175.1M.
- What does products & services — revenue mean?
- This metric tracks the total gross income generated from the sales of a specific product or service segment within a given fiscal period. It serves as a primary indicator of market adoption, commercial success, and the growth trajectory of the specific offering. Monitoring this figure allows investors to assess the revenue-generating capacity of the company's key commercial assets.